MDT-AP-1236
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 20.04
- os_event
- false
- age_years
- 6
- sex
- F
- new_clusters
- S3
- umap1_2d
- -2.072466422
- umap2_2d
- -8.012617968
- umap1_3d
- -3.044605668
- umap2_3d
- -2.412323528
- umap3_3d
- 6.910321876
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.470
- TNFA_SIGNALING_VIA_NFKB+0.460
- ALLOGRAFT_REJECTION+0.440
- CHOLESTEROL_HOMEOSTASIS+0.440
- INFLAMMATORY_RESPONSE+0.440
- ANDROGEN_RESPONSE+0.430
- APOPTOSIS+0.420
- IL6_JAK_STAT3_SIGNALING+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.180
- PEROXISOME-0.060
- APICAL_SURFACE-0.040
- SPERMATOGENESIS-0.040
- HEDGEHOG_SIGNALING-0.020
- DNA_REPAIR-0.010
- FATTY_ACID_METABOLISM-0.010
- MYC_TARGETS_V2+0.010
- XENOBIOTIC_METABOLISM+0.010
- HEME_METABOLISM+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7E198F8E-BBAA-419D-8986-359C109FBE74 | — | — | 0.904 |
| 2 | 4c8b5d7c-d82b-4504-9b9e-3946ca14251e | — | — | 0.897 |
| 3 | MDT-AP-2040 | Med | Medulloblastoma | 0.886 |
| 4 | SRR10900560 | — | — | 0.885 |
| 5 | BS_850BAHH9 | ATRT | — | 0.883 |
| 6 | MDT-AP-0731 | Med | Medulloblastoma | 0.882 |
| 7 | SRR6013494 | — | cohortA1 | 0.880 |
| 8 | BS_KEA474HN | low-grade glioma | — | 0.878 |
| 9 | TCGA-EW-A2FV-01A-11R-A17B-07 | — | C | 0.874 |
| 10 | BS_V4W81SFC | EPN | Supratentorial EPN | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.440 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |